Unspecified GLP-1
Sold by Gatlan · every unspecified glp-1 record
The register has not established whether this program ships a vial, a pen, or another form. That is a gap in our record, not a statement about the company.
What you actually pay
Per month
$125
| Medication · Medical Weight Loss, starting price | $125 |
|---|
Added from the figures recorded below.
Price
| Term | Per month | Charged today |
|---|---|---|
| Medical Weight Loss, starting price “Medical Weight Loss METABOLIC HEALTH Advanced incretin mimetics for sustainable weight management. From $125/mo GET STARTED” | Per month$125 | Charged today$125 |
We earn nothing from this link. Gatlan has no commercial arrangement with Treatment Registry, and its record here is kept to the same standard as every other.
History
One reading so far. A price history appears here after the next verification pass.
- September 2, 2026 — Entry added to the register
Sourcing and terms
| Prescriber | Asynchronous review |
|---|---|
| Cancellation | “While refunds are generally not provided for the Services, Gatlan acknowledges that there may be exceptional circumstances warranting a partial or full refund. In such cases, Gatlan will carefully review the circumstances and, at its sole and absolute discretion, determine whether a refund of any kind is appropriate.” |
Not yet checked: pharmacy, states, membership and consult fee.
Recorded from gatlan.com. Unlike the price rows above, these carry a summary rather than a word-for-word quotation, so they are not shown in quotation marks.
Notes
- 1. September 2, 2026 — /pricing, /weight-loss, and /semaglutide all redirect to the homepage; real content is at /mens-health-products/, /womens-health-products/, and /health-optimization-products/ (identical content on all three). Neither semaglutide nor tirzepatide is named anywhere — the site only says 'GLP-1 and GLP-1/GIP medications' and 'advanced incretin mimetics', and explicitly states 'Gatlan does not offer Retatrutide or any unapproved triple-receptor agonist treatments. Our weight management programs strictly utilize FDA-approved single and dual-agonist therapies' — this phrase suggests brand medication but no brand name (Wegovy/Ozempic/Zepbound/Mounjaro) is ever printed, so drug is recorded as unspecified GLP-1 rather than assumed. No page stating served states was found (checked homepage, all three product pages, and terms). No cancellation-specific page exists; the only relevant text is a discretionary, non-guaranteed refund clause in the Terms of Service.
Treatment Registry is an independent editorial record. It is not a government registry, a licensing body, or a certification. An entry means we recorded what a company published on a given date. It does not mean we recommend the program, and it does not mean the program is approved by anyone.